VNDA

Vanda Pharmaceuticalsdistress 5/10 · elevated risk

$5.30-1%today-45% from 52w high

vandapharma.com533 employeesFounded 2002Washington, DCBiotechnology

Metabolic / Obesity 1

Lead: Sleep Wake Disorders · target NK1

Revenue

$52M

Liquidity

$54M

Runway

0.4 yrs

Shares 1y

+2%

Price & events

-34.5% over 6M

CatalystRating changeDilutionFinancingdashed = today

-0.8%

-2.7%

-10.8%

-20.7%

-33.8%

+9.6%

-15.8%

-73.0%

-61.1%

All

Overview

Market Cap: $319.02M
Volume: 17.91K
52 Week Range: $4.19 – $9.56
Total Shares: 60.14M
Float Shares: 53.84M
Short %: 12.82%
% Held by Insiders: 6.65%
% Held by Institutions: 78.68%
RVOL: 0.02x
Beta: 0.60

Pipeline stages · 9 programs

Trichostatin A

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2026-09

VSJ-110

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2026-09

iloperidone

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2026-10

VQW-765

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2026-12

Tradipitant

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2026-12-01

Tasimelteon Oral Suspension

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2027-11

Milsaperidone

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2028-03

Ponesimod

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2028-08

VCA-894A

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

Pipeline · 16 trials · 11 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2026-09 Estimated 50% readout ~2026-10-16	Phase 2	VSJ-110	Dry Eye	—	recruiting
2026-09 Estimated 50% readout ~2026-10-16	Phase 2	Trichostatin A	Onychomycosis of Toenail	—	active not recruiting
2026-10 Estimated 50% readout ~2026-11-15	Phase 2	iloperidone	Hypertension, Uncontrolled Hypertension	—	recruiting
2026-12 Estimated 50% readout ~2027-02-14	Phase 3	VQW-765	Social Anxiety Disorder (SAD)	—	recruiting
2026-12-01 Estimated 50% readout ~2027-02-14	Phase 3	Tradipitant	Nausea and Vomiting, Obesity	—	recruiting

Show all 16 trials · 11 more ▾

Readout	Phase	Drug	Indication	Enroll	Status
2027-09-30 Estimated 50% readout ~2027-12-14	Phase 3	Tradipitant	Motion Sickness	—	active not recruiting
2027-11 Estimated 50% readout ~2028-01-15	Phase 3	iloperidone	Schizophrenia	—	recruiting
2027-11 Estimated 50% readout ~2028-01-15	Phase 3	Tasimelteon Oral Suspension	Insomnia Disorder	—	recruiting
2027-12 Estimated 50% readout ~2027-12-31	Phase 1	Trichostatin A	Relapsed or Refractory Hematologic Malignancies	—	recruiting
2028-03 Estimated 50% readout ~2028-05-15	Phase 3	Milsaperidone	Major Depressive Disorder (MDD)	—	recruiting
2028-08 Estimated 50% readout ~2028-10-15	Phase 3	Ponesimod	Moderate-to-severe Chronic Plaque Psoriasis	—	recruiting
2026-06	Phase 3	Tasimelteon, Placebo	Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm, Chronobiology Disorders	70	recruiting
2026-03	Phase 1/2	VCA-894A	Charcot Marie Tooth Disease (CMT), Neuromuscular Diseases (NMD)	1	active not recruiting
2025-07	Phase 3	Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension	Autism Spectrum Disorder, Sleep Disorder, Neurological Disorder, Sleep Disturbance	100	unknown
2025-06-30	Phase 3	Tasimelteon, Placebo	Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm, Chronobiology Disorders, Gene Mutations and Other Alterations Nec	60	recruiting
2025-02-21	Phase 3	Tradipitant, Placebo, Open Label Tradipitant	Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis	992	completed